The increase in Moderna's average price target reflects a positive sentiment among analysts, despite the company's recent financial downturn. The optimistic outlook is likely due to Moderna's strong pipeline and the potential of its mRNA technology. However, the financial challenges highlighted, such as the significant revenue decline and below-average profitability metrics, could temper short-term gains. The overall positive score is based on the belief that the innovative aspects of Moderna's business may outweigh the current financial challenges in the eyes of investors.